The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
Ricky M. Trigg(GlaxoSmithKline (United Kingdom)), Suzanne D. Turner(MRC Laboratory of Molecular Biology)
Cited by 42
Related Papers
Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
|Cancers|2018|86
Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant–Associated Anaplastic Large-Cell Lymphoma
|American Journal Of Pathology|2019|54